CTIM-76 Receives FDA Fast Track Designation for Platinum‑Resistant Ovarian Cancer
CTIM‑76 has received FDA fast track designation for platinum‑resistant ovarian cancer.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements